Pre-IPO bout to value PharmEasy at $6 billion

Know more→

Mobility Energy and Transportation

Healthcare and Lifesciences

Pre-ipo bout to value pharmeasy at $6 billion

14 Sept 2021

1 min read

PharmEasy is finalising a $200-million primary funding round ahead of its initial public offer (IPO) and is in talks with marquee investors from the US and South East Asia, such as Blackstone, BlackRock, Amansa Capital, Janchor Partners and OrbiMed, multiple people in the know told ET.

Simultaneously, the country’s largest e-pharmacy is also stitching up a secondary transaction of up to $100 million, buoyed by high interest from pre-IPO investors looking to come on board, sources said. PharmEasy is likely to be valued at around $6 billion post the funding round, creating a benchmark valuation ahead of a public listing. It was last valued at $4.2 billion in June.

Click here to read the full article on The Economic Times

Disclaimer: The text, images and content here have been reproduced from the original publisher. Praxian Global Private Limited does not claim any ownership or right to use of this content and the rights belong to the publisher. We have contributed our perspectives, which are often proprietary, to the content publisher. We or the publisher have no obligation to update or refresh the content or our perspectives shared herein.

Ready to talk?

I want to talk to your experts in:

We work with ambitious leaders and transformative clients who are defining the future. Together, we achieve extraordinary outcomes.

Pre-IPO bout to value PharmEasy at $6 billion | PraxisGA